Investor relations
Investor relations news
2025.05.08
JCR Pharmaceuticals to Present at the American Society of Gene and Cell Therapy 28th Annual Meeting
2025.05.07
Notice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by the U.S. FDA
2025.04.25
Notice of Election of Candidate for New Audit & Supervisory Board Members
2025.03.27
JCR Revises Full-Year Consolidated Forecast for FY2024
2025.02.27
Change in Duties of Corporate Officers, Organizational and Personnel Changes
2025.02.25
Notice Concerning the Start of Construction of a New Drug Product Plant
2025.02.21
JCR Pharmaceuticals Proudly Supports Rare Disease Day 2025
2025.02.12
Notice of Partial Correction to “FY2024 Third Quarter Consolidated Financial Results Conference Call Material”
2025.02.05
JCR Pharmaceuticals’ Research Presentations at WORLDSymposium 2025 Showcase Research from Its Investigational Treatments for LSDs
2025.02.04
FY2024 Third Quarter Consolidated Financial Results Conference Call Script
Discover our past news and updates, including the latest announcements and historical insights.
Explore past investor relations materials, from reports to presentations.